Introduction
Who should attend
Course Features
Related Courses
About in and out licensing
Course Upgrade
This licensing online training course provides advanced practical real life training on inlicensing and outlicensing deal. In fact the course covers entire strategic aspects of the in and out licensing deal. Hence, pharmaceutical inlicensing and outlicensing course guides each participant through licensing deal. Hence, it ensures in-depth understanding on profiling to due diligence process. Moreover, the course will focus on portfolio analysis and strategies for successful product pipeline management. Above all, the course provides hands on training on biopharmaceutical brand valuation tools and techniques.
- Course Code: RYD-022
- Title of the training: Certificate course in Inlicensing and Outlicensing in Pharmaceutical and Biopharmaceutical Industry
- Duration of the course: 1 Month
- Eligibility: Any body who wants to acquire inlicensing and outlicensing related job competency should attend the course.
- Certification: Certificate will be provided at the end of the successful completion of the course.
Self Paced Learning
Being self paced learning, it is convenient for working executives. In fact, it allows the user to stop and start at their leisure. More importantly, the course is designed to challenge students to apply what they have learned through the use of interactive exercises, reflection questions and a final assessment at the end of the course.
Who should attend this biopharma inlicensing and outlicensing training?
- First of all, this inlicensing and licensing course is ideal for Pharmaceutical and Biopharmaceutical professionals working in business development, strategic management and licensing department.
- Secondly, this course will be ideal for Biopharmaceutical R&D professional to understand biopharma inlicensing and outlicensing deal.
- In fact, it is ideal resource for those wishing to update their knowledge on portfolio management strategies.
- Also, this will provides cutting-edged training for Pharmaceutical project management and Biopharmaceutical Project Management.
Features of the Course:
- Orientation to practical understanding licensing deals – specifically in inlicensing and outlicensing in pharma and biopharma industry
- Simulation to real life Regulatory Strategic planning for licensing in pharma business.
- Course provides comprehensive understanding on market forecasting, valuation techniques and deal financial analytics.
- Practical training in drafting of licensing deals.
- Focus on due diligence in pharmaceutical and biopharmaceutical licensing deals.
Here are some related courses:
- Biopharma Global Business >> Learn more
- Pharma Business Development and Licensing >> Learn more
- Biopharmaceutical Corporate and Brand Valuation >> Learn more
- Pharma Global Management >> Learn more
- Pharmaceutical Brand Management Course >> Learn more
- Market Access and Pricing >> Learn more
- Forecasting Tools and Models in Biopharma Industry >> Learn more
- Biopharma Valuation Training >> Learn More
- Medical Device Global Business >> Learn More
What is in licensing and out licensing?
If I license a product from Company A and there is a Company B who will get the license for that product from Company A. Then, Company B is in-licensing it and Company A is out–licensing it.
What is out licensing in pharma?
Out–licensing is more focused on opening up the delivery pipeline to assist you with getting your drug “out the door.” Out–licensing encompasses finding a partnership, or partnerships, that will help identify your target market and assist you in getting your product into the right hands.
What does Licensing mean in business?
Definition: A business arrangement in which one company gives another company permission to manufacture its product for a specified payment. There are few faster or more profitable ways to grow your business than by licensing patents, trademarks, copyrights, designs, and other intellectual property to others.
Can I extend this course for more than 1 month?
In general, this course is having duration of 1 month. But you can increase your course subscription period of your need. What we mean, if you require to increase the course duration for 2 month or 3 month, you can do so. Kindly keep in touch our support team at info@royed.in, they will assist you further.
Course Upgrade
From PG Certification in Pharma Marketing, one can upgrade to one of the following courses.
Course upgrade is possible by paying a difference in course fees. Hence, one will not be paying the full course fees of pharma global management. Course participants need to pay only the difference in course fees.
Section 1Core Fundamental Sessions
Lecture 1Introduction | Download modules
Lecture 2Introduction to Licensing and Technology Transfer
Lecture 3Patents Vs. exclusivity
Lecture 4R&D Process & Introduction to drug discovery
Lecture 5Patent & Exclusivity - Strategic Understanding | Patent Restoration| Orphan Drug Exclusivity (ODE) | NCE & NCI Exclusivity | GAIN Exclusivity | Pediatric Exclusivity | 180 days exclusivity
Lecture 6Portfolio Management in R&D Lifecycle
Lecture 7Evergreening - Patent Life Extension Strategies
Lecture 8Compulsory Licensing
Lecture 9Licensing & Technology Transfer
Lecture 10In-Licensing Vs. Outlicensing
Lecture 11LOE Strategies for Innovator Brands with case study
Lecture 12Types of Deals from Discovery to Commercialization
Lecture 13Sales Forecasting in Life Science Industry
Lecture 14New Product Forecast Algorithm
Lecture 15Patient Based Forecasting Model | Applying more filters and variable
Lecture 16Prescription Based Forecasting Model | Differences between Patient Based and Prescription Based Forecasting Model | Which model to use and when?
Lecture 17Prevalence Vs. Incidence Model
Lecture 18EPI Based Forecasting | Sales Based Forecasting | When and where to apply which forecasting model
Lecture 19Sales Forecasting Tools | New Product Forecasting | In Market Forecasting
Lecture 20Market Size Assignment 1 [Oncology Brand] - Applying sales forecasting tools to carry out next 6 years sales forecast | Excel Based Model
Lecture 21Market Size Assignment 2 [Asthma Brand] - Applying sales forecasting tools to carry out multiple years sales forecast | Excel Based Model
Lecture 22Patient Based Model Vs. Patient Flow Model | Critical Differences in Model | Concept of Black Box in Patient Flow Model | Application of both model
Lecture 23Concomitancy and polypharmacy | How it alter the basic forecasting algorithm | Practical Working | Comorbidity
Lecture 24Forecasting Techniques | Simple Conjoint-type Models | Zipf's Law | Simple Elasticity Model | The Bass Model |Simple Extrapolation
Lecture 25Bottom-up or Top-down Forecasting | LRx | Significance of LRx data analysis
Lecture 26Simulation on Bottom-up forecasting
Lecture 27Assessment on Bottom-up forecasting
Lecture 28Oncology Brand Forecasting
Lecture 29QALY | How to calculate QALY | Importance and Significance
Lecture 30ICER | How to calculate ICER | Importance and Significance | Incremental Therapy Value Proposition
Lecture 31Patent Cliff | How to calculate the patent cliff
Lecture 32Portfolio Based Forecasting | Forecasting Model Development in Excel
Lecture 33Data Exclusivity and Market Protection - Supplementary Patent Protection, Exclusivity, 6/10 Rule, 8+2+1 Formulae
Section 2Advanced Learning Sessions
Lecture 34Types of Strategic Alliances: Unilateral technology licensing | Cross technology licensing | R&D contracts | R&D collaborations | Minority-equity-based R&D alliances | JV | Manufacturing and marketing agreements of big pharma firms with dedicated biotechnology firms
Lecture 35Market Size Determination - Market Share | Relative Market Share | Total Vs. Actual Vs. Penetrated Market
Lecture 36Licensing - Advance Learning
Lecture 37Business Development Job Functionality | Strategic Planning Process | Knowledge Area of Business Development | Lead targeting | Licensing term sheets
Lecture 38Portfolio Management Process | Portfolio Characteristics | Portfolio Analysis | Balancing the Portfolio | BD and Strategic Planning Department
Lecture 39Identifying the corporate Need of business development | Objective – Strategy - Tactics | Portfolio constraints | SWOT | Numerical SWOT
Lecture 40Profiling and Searching | Objectives | Search Database | Creating Opportunity Anatomy for deal analysis | Mind Mapping | Searching Tools and Techniques - Web Search | Conference | Confidentaility - CDA | MTA
Lecture 41Numerical SWOT Practical training
Lecture 42Modelling and Deal Valuation - Top Down Model | Epidemiology data method | Complex Model | Forecasting | Heuristic or ‘prophesy’ method | Different value perspectives | Deal Structuring Structuring the deal
Lecture 43Royalty Management - Royalty structuring | Royalty Calculation Method| Tiered Royalties | Terms | Royalty Reductions | Royalty Stacking - Concept and Calculation | Minimum Annual Royalties | Reach through royalties
Lecture 44Average Royalty Rate
Lecture 45Factors affecting royalty rate
Lecture 46Distribution Licensing | Geography | Indication Splitting | Execlusive and Non-Exclusive Licensing | Sub Licenses
Lecture 47Acquisition in Pharma | Product Acquisition| Company Acquisitions| Steps in acquisition | Financing acquisition deals | Trademark Assignment Process
Lecture 48Licensing Term Sheet | Content Structuring | Sample Term Sheet
Lecture 49Licensing Payment Scheduling: Different Types
Lecture 50Valuation Methods: DCF | rNPV | Sunk Cost Method | Comparables | Sum of Parts | Deterministic Vs. Probabilistic rNPV | Peak Sales - Max-Min Approach
Lecture 51Valuation Methods: EBITDA method of valuation | Enterprise Value and Enterprise Multiple Calculation
Lecture 52Business Development Simulation and Decision Making | Early Stage VS. Late Stage Valuation Methodology | Stair Step Model
Lecture 53Licensing Agreement : Confidentiality Agreement | MTA | A deed of Assignment | Exclusive | Non-Exclusive License | Sole License | Components - Terms - Duration - Key Considerations
Lecture 54Step By Step Implementation of Licensing Deal by Business Development Team
Lecture 55Value Share Principle | Discounting of licensing deal | Discount Rate
Lecture 56DCF Calculation : Concept and Calculation - Step by step understanding
Lecture 57Net Present Value (NPV) method : Calculation
Lecture 58Risk-Adjusted Discount Rate Method - Calculation | Concept of Risk Premium
Lecture 59Valuation Metric - P/E Ratio and EPS : Calculation
Lecture 60Comparable Company Analysis method : Calculation
Lecture 61EBITDA Multiples | Importance in Pharma Biopharma BD&L | Calculation | Benchmarking EBITDA multiplies | Sourcing EBITDA multiples | Decoding EBITDA multiples value in different types of pharma and biopharma organizations
Lecture 62Pipeline Benchmarking | Significance and Importance in Bio Pharma BD&L | Analyzing sample portfolio | Comparative outcome in business development
Lecture 63Comparative pipeline benchmarking analysis | Level of Benchmarking | Primary - Secondary - Tertiary Benchmarking Metrics | Case Based Analysis of three companies comparative pipeline benchmarking
Lecture 64Pipeline Diversity Scores | Significance | How to Calculate | Comparative Study of Pipeline Diversity Scores
Lecture 65Real Time Portfolio and Pipeline Tracker
Lecture 66Research Productivity Index | Concept | Significance | Calculation Methodology | Comparative RPI benchmarking Exercise
Lecture 67WACC in Biopharma Valuation | Significance | WACC benchmarking
Lecture 68WACC Calculation | Step by Step Calculation | Insight on WACC components
Lecture 69rNPV Model | Step by Step Calculation | Insight on Probability and Cumulative Probability | Factoring WACC for Discounting
Lecture 70Probability and Cumulative Probability | Calculation | Benchmarking | Factoring for WACC and rNPV
Lecture 71Real Options Valuation (ROV) for Biopharma assets | Model Development | Calculation | Case Based Insight in the context of inlicensing and outlicensing | Early stage asset valuation with ROV
Lecture 72ROV Scenario Based Case Study
Lecture 73Biotech Decision Tree Model with Decision Reasoning
Section 3Innovation Management - Patent - Valuation in Pharma and Biopharma Industry
Lecture 74Introduction to Intellectual Property in Life Sciences | Types of IP | Introduction to Patent Portfolio Strategy
Lecture 75Global Pharmaceutical Patent Landscape | Strategic Overview of Global Patent Filing and Protection
Lecture 76Global Pharmaceutical Patent Filing Strategy
Lecture 77PCT Patent Filing Flow
Lecture 78Patentability Criteria in Pharmaceuticals | Practical Case Study
Lecture 79Patent Law Framework for Pharmaceuticals
Lecture 80Understanding and Decoding Section 3(d) of the Indian Patent Act | Case Based Analysis
Lecture 81Evergreening vs Genuine Innovation in Pharmaceutical Patents | Evergreening and Genuine Innovation Evaluation
Lecture 82Pharmaceutical Patent Lifecycle - Integrated Layer Strategy
Lecture 83Blockbuster Drug Patent Thicket Strategy
Lecture 84Types of Pharmaceutical Patents | Patent Layering StrategiesTypes of Pharmaceutical Patents
Lecture 85Understanding Patent Searching Process
Lecture 86IPC and CPC - Importance and Significance in Patent Search
Lecture 87IPC Structures for Pharmaceutical Patents
Lecture 88Freedom-to-Operate (FTO) | FTO Risk Assessment | Strategic Management
Lecture 89FTO Decision Tree – Generic Drug Launch Strategy
Lecture 90Fundamental of Pharmaceutical Patent Drafting | Structure | Component | Claim Anatomy | Effective Claim Writing
Lecture 91Pharmaceutical Patent Risk Management Framework
Lecture 92Patent Claim Coverage - Practical Example
Lecture 93Pharmaceutical Patent Filing Procedure and Global Filing Strategy | PCT Filing | Timeline
Lecture 94Advanced Understanding on Patent Opposition and Patent Litigation in Pharmaceutical Domain
Lecture 95Patent Prosecution and Handling Examiner Objections
Lecture 96Pharmaceutical Patent Portfolio Management | How to build and manage pharma patent portfolio
Lecture 97Pharmaceutical Patent Valuation and Licensing
Section 4Advanced Licensing Management in Biologic
Lecture 98Biological Licensing Application (BLA) | 351(a) application | Form 356h | Differentiation with NDA | Timeline | Handling FDA queries
Lecture 99Abbreviated Biosimilar Application - 351(k): Advance Strategic Planning Process : Originator Vs. Biosimilar Development and Regulatory Approval Process | Reference Biologic | Purple Book | Data Requirements
Lecture 100Purple Book: Significance | Searching | Assignments
Lecture 101Biosimilar Approval and Patent Management | Strategic Pathway of Patent Negotiation and Litigation in Biosimilar Approval | Patent Dance | FAQs on Biologic Patent Management
Lecture 102Biosimilar launch case study | Patent Dance Framework
Lecture 103Biosimilar Launch Framework
Lecture 104Biosimilar 180 Day Notice
Lecture 1053(A) List | Significance | Importance | How to interpret
Lecture 106Steps to win over innovator patents | Step wise planning
Lecture 107Hands on Training on Reference Biologic Patent | Classify RPS Biologic Patents | Case Simulation
Lecture 108How to work on RPS’s Patent | Walkthrough | Case Study
Lecture 109Analysis of Biologic Patents | Work Assignments
Lecture 110Patent Thickets | Concept | Implication | Case Based Learning
Section 5Strategic Discussions, Case Studies, Simulations
Lecture 111BD&L Ecosystem in Pharma: How Licensing Actually Happens
Lecture 112Why do most high-value deals happen before Phase III?
Lecture 113What are the risks of ignoring early-stage assets?
Lecture 114In-Licensing vs Out-Licensing vs Co- Development: Strategic Decision-Making in BD&L
Lecture 115How would you identify a high-potential licensing opportunity?
Lecture 116Understanding Asset Classes in Licensing: Strategic Selection & Deal Implications
Lecture 117Asset Scouting Framework: Identifying High-Value Licensing Opportunities
Lecture 118BD Simulation Dataset – 50 assets licensing pipeline | Case Simulation | Scoring, shortlisting, valuation, and deal decision simulations
Lecture 119Case Study – Deal Structuring - 3 Different Assets
Lecture 120Selecting the Right Therapy Area | Market Intelligence for High-Impact Licensing Decisions - Case Based Analysis
biopharma business development, biopharma business development course, course for pharma business development manager, in licensing and out licensing pharma, inlicensing, outlicensing
